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The concept proposing a major role for interorgan crosstalk
as a link between dysmetabolism and inflammation largely
builds on two major conceptual advances that developed
mainly in the last two decades.The first one is the recognition
that endocrine-type crosstalk exists between virtually all
organs and tissues, extending way beyond very specific,
“classical” endocrine glands. This has relied on various lines
of experimental approaches, including “omics” types of data,
revealing that a large fraction of the expressed genome of
many tissues encodes known and predicted secreted proteins.
Complementarily, tissue-specific genetic manipulations pro-
vided in vivo evidence for the ability to alter the function
of a tissue distant from the site directly affected by the
genetic intervention. The second conceptual advance is the
huge expansion in our understanding of the homeostatic-
physiological roles, as well as the pathophysiological involve-
ment, of the immune system in diverse types of diseases.
In this context, two decades ago, the finding that tumour
necrosis factor-𝛼 (TNF-𝛼) is overexpressed in adipose tissue
of obese mice provided the first clear link between obesity
and chronic inflammation [1]. Almost at the same time, the
discovery of leptin, the first adipokine that signals through a
cytokine receptor familymember, sparked the understanding
that inflammatory changes within adipose tissue may alter
the way this tissue communicates with various organs, even
the brain [2]. More recently, a wealth of data established
the concept that obesity is associated with systemic and
tissue-level low-grade chronic inflammation, initially recog-
nized by adipose tissue infiltration with inflammatory cells
in response to an excessive energetic nutrient load [3, 4].
The concept of “metabolic inflammation” or “metaflamma-
tion” was eventually formulated and fueled by examples of
specific mechanisms tying metabolic mediators to inflam-
matory cascades and inflammatory mediators to alterations
in metabolic regulation [5]. The metabolic inflammation,
possibly initiated in response to excess calories/high fat
feeding in the adipose tissue, may subsequently involve
other metabolic organs such as the liver, skeletal muscle,
and pancreas, contributing to metabolic dysfunction and
insulin resistance. This multiorgan involvement of obesity-
associated inflammation presents a challenge to researchers
attempting to clarify the complex signaling mechanisms of
the interorgan crosstalk leading to metabolic dysfunction.
Alongside inflammation pertaining to “metabolic” organs,
studies published during the past decade have convincingly
demonstrated a pathophysiological role for the inflamma-
tory response in the development of cardiovascular disease
(CVD), the most important complication of the metabolic
syndrome and diabetes [6]. In addition, a multitude of
mediators of metabolic inflammation have been found to
modulate vascular homeostasis, suggesting further mecha-
nisms of interorgan crosstalk between metabolic tissues and
the vasculature. Therefore, the low chronic inflammatory
state may be responsible for both insulin resistance and
endothelial dysfunction, providing deleterious connections
between inflammation and metabolic/CVD processes.
This special issue aims to highlight selected topics project-
ing on advances in our current understanding of the players
involved in interorgan communication in obesity-associated
metabolic diseases.
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In their review, S. Raschke and J. Eckel present an update
on bioactive proteins secreted by adipose tissue and skeletal
muscles (termed “adipokines” and “myokines”, resp.), reveal-
ing their peculiar interplay, which represents a yin/yang-type
balance: adipokines, upregulated in the obese state, tend to
contribute to establish a chronic inflammatory environment
that promotes pathological processes such as atherosclerosis
and insulin resistance, whereas myokines seem to largely
counteract these effects of adipokines, likely reflecting their
essential regulatory role in muscle metabolism during con-
traction. Yet, as more than half of the described myokines are
also secreted by adipocytes, the authors suggest to term these
cytokines “adipo-myokines,” whose beneficial or adverse
effects are strictly dependent on their local concentration and
kinetics.
A confirmation of this general principle can be found
in the review by T. Romacho and colleagues describing the
cellular effects of the recently identified adipokine Visfatin/
Nampt. Within the adipose tissue, Visfatin/Nampt is not
only synthesized and released by adipocytes but also by
inflammatory cells, like activatedmacrophages. Very recently,
Visfatin/Nampt expression has been reported in cardiomy-
ocytes, hepatocytes, andmyoblasts, thus suggesting its poten-
tial role in an even more intricate interorgan metabolic
crosstalk. The authors summarize convincing evidence for
its deleterious effects on the cardiovascular system, including
monocyte/macrophage activation, vascular inflammation,
and remodeling. At the same time, the authors quote several
papers on beneficial actions of Visfatin/Nampt in ischemia-
related clinical conditions.
In their research article, R. Schlich and colleagues inves-
tigate the role of vascular endothelial growth factor (VEGF).
This well-known growth factor is also released from visceral
adipose tissue in obesity and from perivascular adipose
tissue of patients with type 2 diabetes and may constitute
yet another interorgan mediator, in this instance, linking
adipose tissue inflammation to abnormal vascular smooth
muscle cells (VSMC) proliferation. Using a model of VSMC
proliferation induced by adipocyte-conditioned medium
(CM), the authors clearly show that this effect was mainly
mediated byVEGF.Moreover, they demonstrate that CMalso
induced the release of VEGF by VSMC, which in turn could
stimulate proliferation via “second-level” autocrine/paracrine
communication.
Another immune system (complement-related) medi-
ator, adipose-derived factor with potential autocrine/para-
crine and endocrine functions is the acylation stimulating
protein (ASP).Using an in vivomodel of diet-induced obesity,
which mimics a typical unhealthy western diet with both
high fat and high sucrose intakes, A. Fisette and colleagues
demonstrate the paradoxical effects of acute administration
of ASP. Particularly, they show that ASP supplementation
improved glucose clearance through a short-term insulin
sensitizing process in spite of its proinflammatory properties,
as demonstrated by increased serum and tissue levels of IL-6
and TNF-𝛼. This may represent a growing current notion
expanding our view of the links between inflammation and
metabolic regulation [7].
E. Benetti and colleagues focus their attention on the
deleterious effects of high sugar intake. They demonstrated
that mice chronically fed a sugar-enriched diet develop
dyslipidemia and hyperinsulinemia. These metabolic effects
were associated with increased infiltration of inflammatory
cells into skeletal muscle. Most notably, dyslipidemia and
hyperinsulinemia could be prevented by oral administration
of a selective agonist of the nuclear receptor peroxisome
proliferator activated receptor-𝛿, which positively correlated
with increased muscular levels of the myokine FGF-21, a
mediator with expanding roles in metabolic and energy
regulation [8].
The role of diet components/additives in affecting sub-
clinical inflammation and insulin resistance is further investi-
gated by S. Bhattacharyya and colleagues.They provide novel
insights into themechanisms of carrageenan-induced inflam-
mation. Interestingly, mice lacking Bcl10, a key molecule
in the activation of the inflammatory cascade in epithelial
and immune cells, were partly protected from carrageenan-
induced inflammation, and such effect was related to an
inhibition of both canonical and noncanonical pathways of
NF-𝜅B activation.
A potential intestinal participation in the pathogenesis of
insulin resistance is more widely addressed in the review by
B. M. Carvalho and colleagues, showing how gut microbiota
modulation promoted by a bacterial diversity shift mediated
by overnutrition increases intestinal permeability, culminat-
ing in inflammation and insulin resistance. Herein, activation
of inflammatory pathways by gut-derived bacteria products
and metabolites is discussed, with particular reference to the
key role of the inflammasome multiprotein complex. This
recently identified novel player of the intercellular crosstalk
linking chronic inflammation tometabolic disease pathogen-
esis is also the main topic of the review article by B. Benetti
et al.
The role of selective inflammatory mediators in pancre-
atic 𝛽-cell dysfunction has been investigated in two different
research articles. L. Quintana-Lopez and colleagues demon-
strate in cultured islet 𝛽-cells that nitric oxide (NO) is an
important mediator of the antiproliferative effect induced by
proinflammatory cytokines, such as IL-1𝛽, IFN-𝛾, and TNF-
𝛼. In keeping with these in vitro data, the same authors
report that early treatment of biobred rats (inbred laboratory
rats spontaneously developing autoimmune type 1 diabetes)
with the NO synthase inhibitor L-NMMA improved 𝛽-cell
proliferation compared to untreated animals. In addition,
A. Puddu and colleagues demonstrate that the detrimental
effects evoked by exposing the hamster pancreatic 𝛽-cell
line HIT-T15 to a pool of advanced glycation end products
are prevented by cell treatment with the incretin hormone
glucagon-like peptide-1 (GLP-1), which was shown here to
restore selective pathways regulating proinsulin production.
Two additional articles discuss the molecular mecha-
nisms underlying the positive association between obesity-
associated insulin resistance and cardiac hypertrophy or
destructive periodontal disease. Specifically, M. Asrih and
colleagues report evidence on the dual role of the cytoso-
lic signaling proteins mitogen-activated protein kinases in
inducing synthesis of both specific mediators of cardiac
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hypertrophy (such as the gap junction protein connexin
43 and the cardiotrophin-1) and glucose transporters (by
affecting the insulin signaling pathway) in cardiomyocytes,
thus suggesting selective intracellular mechanisms of cardiac
adverse remodeling associated with insulin resistance. R.
Khosravi and colleagues offer in their overview potential
explanations for the higher risk of destructive periodontal
disease in obesity and insulin resistance; that is, they provide
evidence for TNF-𝛼 and IL-6 as crucial inflammatory medi-
ators connecting these different diseases.
Finally, R. Murphy and colleagues propose an intriguing
approach to better elucidate the firm cause-effect relation-
ships between obesity and insulin resistance development.
In fact, although obesity is often reported to confer the
highest risk for the development of metabolic diseases, the
key events in this process are difficult to disentangle from
compensatory effects and epiphenomena.The authors of this
review support the suggestion that a deep investigation on key
monogenic disorders may significantly contribute to unravel
the pathogenic links between the defined molecular defect
and the related exaggerated metabolic disorders, without the
confounding effects of all the other components. For instance,
they show how the key role of components of pancreatic 𝛽-
cell function can be confirmed by evidence, demonstrating
that common monogenic pancreatic 𝛽-cell defects lead to
early onset of diabetes even in the absence of obesity-related
insulin resistance.
Overall, we hope that readers will find the articles in this
issue not only interesting but also instructive. They might
even serve as a source of inspiration for future investigations
aiming to further elucidate the intricate inflammatory mech-
anisms operational in the pathogenesis, and potentially also
the resolution, of obesity-associated insulin resistance and
type 2 diabetes. Such lines of research may raise hope for
discovering new strategies to battle one of the key drivers of
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